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Available online 29 July 2015AbstractScirrhous hepatocellular carcinoma, which is rare, has been identified as one of the histological subtypes of hepatocellular carcinoma. The
typical CT and MRI imaging features of SHCC is hypo-attenuating or hypointensity masses with peripheral enhancement in the arterial phase,
followed by centripetal enhancement during portal venous and equilibrium phases [1,2]. In this report, we present a 65-year-old woman suffering
from SHCC with rare CT and MR imaging features.
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Scirrhous hepatocellular carcinoma (SHCC), which is rare,
has been identified as one of the histological subtypes of he-
patocellular carcinoma (HCC). SHCC is pathologically char-
acterized by an abundant fibrous stroma in which cords of
neoplastic tumor cells are embedded [3]. Diffuse fibrosis
(scirrhous change) is frequently reported in cases of hepato-
cellular carcinoma treated by various anticancer therapies such
as chemotherapy, irradiation and transcatheter arterial embo-
lization, but similar changes could also be occasionally
observed in HCC without anticancer therapies. Histologically,
SHCC is characterized by diffuse fibrosis along the sinusoid-
like blood spaces with varying degrees of atrophy of tumor
trabeculae [4]. To date, imaging studies, such as CT and MRI,
about the diagnosis of SHCC are extremely rare. Due to the* Corresponding author. Department of Radiology, Beijing YouAn Hospital,
8, Xi Tou Tiao, Youanmen wai, Fengtai District, Beijing, 100069, China. Tel.:
þ86 10 83997337.
E-mail address: Lihongjun00113@126.com (H.-J. Li).
http://dx.doi.org/10.1016/j.jrid.2015.07.003
2352-6211/© 2015 The Authors. Production & hosting by Elsevier B.V. On behalf
open access article under the CC BY-NC-ND license (http://creativecommons.org/rarity and general unawareness of scirrhous hepatic carci-
noma, it might be misdiagnosed as one of the other malignant
hepatic tumors with abundant fibrosis. Here, we present a case
of poorly differentiated SHCC with atypical CT and MRI
findings.
2. Case report
A 65-year-old woman with chronic liver disease was
admitted in January 2013 for further examination of a 50-mm
hypoechoic mass in segment six (S6). The patient had no
history of alcoholism, blood transfusion or drug abuse. On
admission, physical examination showed no remarkable ab-
normalities. Laboratory studies disclosed that HBsAg, HBeAb
and HBcAb were positive, and hepatitis C virus was negative.
Other laboratory studies disclosed no abnormalities. The levels
of tumor markers were as follows: AFP 4.5 ng/mL (normal,
<10 ng/mL), CA19-9 15.9 U/mL (normal, 0e37 U/mL).
US disclosed a 50-mm hypoechoic mass in S6. MDCT
revealed a low-density lobulated mass with a distinct margin on
the non-enhanced scanning, and light heterogeneousof Beijing You’an Hospital affiliated to Capital Medical University. This is an
licenses/by-nc-nd/4.0/).
Fig. 1. Contrast-enhanced CT. Light heterogeneous enhancement in the arterial phase (A), ring and prolonged enhancement in the interior of the tumor during
portal venous and equilibrium phases, and a no enhanced low-density area in the center of the tumor (B and C).
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enhancement in the interior of the tumor during portal venous
and equilibrium phases, as well as an enhancement-free low-
density area in the center of the tumor (Fig. 1). There was a
surface retraction adjacent to the tumor. MRI revealed homo-
geneous hypointensity at T1WI (FLASH) and heterogeneous
hyperintensity at fat-suppressed T2WI (BLADE) and hetero-
geneous hyperintensity at DWI (EPI, b ¼ 800 s/mm2) se-
quences. Contrast-enhanced MRI (3D-VIBE) also revealed
light heterogeneous enhancement in the early phase and pro-
gressing ring enhancement in the interior of the tumor in the
portal venous phase and equilibrium phase (Fig. 2). Based on
these imaging findings, the tumor was diagnosed as a hepatic
neoplasm only. We conducted right hepatic segmentectomy for
the SHCC and chemotherapy after operation. Macroscopically,
the mass was whitish in color, solid, lobulated and not
encapsulated (Fig. 3). Histologically, the tumor was poorly-
differentiated HCC characterized by typical cytological andFig. 2. Contrast-enhanced MRI. Homogeneous hypointensity at T1WI (A); heteroge
in the early phase(C); and progressing ring enhancement in the interior of the tum
5 month at DWI (b ¼ 800 s/mm2) sequence (F).structural atypia with dense fibrosis (Fig. 4). Immunohis-
tochemically, the tumor was positive for hepatocyte paraffin 1
(Hep par 1), GPC-3, cytokeratin 7(CK7), cluster of differ-
entiation 34(CD34), cluster of differentiation 56 (CD56), and
negative for cytokeratin 19(CK19), CD54, CD133, vimentin,
SYN, and Ki-67 about 50%. From the above findings, the
tumor was diagnosed as SHCC. Intrahepatic recurrence has
been observed over a period of 5 months (Fig. 2F). Then we
conducted CT-guided radiofrequency ablation for the
recurrence.
3. Discussion
Since scirrhous hepatic carcinoma was firstly introduced by
Omata, only a few reports have described this rare malignant
hepatic tumor [5]. Imaging studies, such as MDCT and MRI,
for the diagnosis of SHCC remain extremely rare [1,5].
Regarding terminology, SHCC was often confused withneous high intensity at fat-suppressed T2WI (B). Revealed light heterogeneous
or in the portal venous phase (DeE); Intrahepatic recurrence over a period of
Fig. 3. Gross findings of the resected tumor. The mass whitish in color, solid,
lobulated, no encapsulated.
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variety of tumors with sclerotic change and hypercalcemia
arising from non-cirrhotic livers [5]. However, sclerosing he-
patic carcinoma did not constitute a distinct histopathological
entity as some of these tumors appear to be HCC, but others
cholangiocarcinoma. Therefore, it was deleted from the WHO
classification [4,6]. Matsuura et al. [7] defined ‘scirrhous’ as
an area with scattered cords or nests of tumor cells in an
abundant fibrous stroma, which accounted for more than a
quarter of the entire area, as shown by light microscopy and
Masson trichrome staining. Next, scirrhous HCC was defined
as a tumor in which the scirrhous area made up more than half
of the largest section. WHO has defined SHCC as a scirrhous
growth pattern characterized by marked fibrosis along the
sinusoid-like blood spaces with varying degrees of atrophy of
tumor trabeculae [6].
Fibrosis in the tumor can be classified into the following
three patterns: (1) fibrosis extending along the sinusoid-like
blood spaces with atrophy of tumor trabeculae; (2) dense
fibrosis with hyalinization separating the tumor into various
sizes of tumor nests; and (3) fibrosis with a lamellar pattern.Fig. 4. Histologically, poor-differentiated tumor. The tumor presented diffuse fibrosi
stroma (A), and diffuse loose connective tissue at the inside(B). (Hematoxylin andMany of these three types of fibrosis coexisted to various
degrees in most cases [8].
Previous research presented that pathologically confirmed
SHCC accounted for 4.5% of the total confirmed cases of
hepatocellular carcinoma in the same period. Furthermore it
was unveiled that the prognosis of SHCC was as good as that
of HCC [2]. Besides, the clinical backgrounds of SHCC are
not significantly different from those of non-SHCC with re-
gard to age, gender, positive rates to hepatitis viruses, AFP
levels, Child-Pugh classification, and stage of tumor-node-
metastasis [8].
The proportion of fibrous capsules in the scirrhous HCCs
was significantly lower than that in ordinary HCCs. Necrosis
was found in significantly lower proportions in the scirrhous
HCCs than in ordinary HCCs. Portal tracts in the tumor were
unveiled in scirrhous HCCs at a significantly higher rate than
in ordinary HCCs [7]. SHCC is characterized by its unique
location. Most SHCC are peripherally-located and surface
retraction adjacent to the tumor is common [2,8].
Imaging studies for (about) SHCC are rare. Kim et al. [1]
reported that for CT enhancement pattern, all tumors showed
hypoattenuating masses with peripheral enhancement in he-
patic arterial phase, followed by centripetal enhancement
progressively during portal venous and equilibrium phases.
Centripetal enhancement during portal venous and equilibrium
phases appeared to be either concentric or irregular. In the
author's previous study [2] about CT and MRI features of
SHCC, the dynamic enhanced CT and MRI appearances of
SHCC can be divided into 3 types: (1) Peripheral rim
enhancement in the arterial phase, followed by centripetal
enhancement during portal venous and delayed phases (46.9%,
15/32). (2) No enhancement or light heterogeneous enhance-
ment in the interior of the tumor in the arterial phase, pe-
ripheral enhancement and separate enhancement in the interior
of the tumor on the delayed phase (46.9%, 15/32). (3) Small
nodular-like enhancement in the early phase and wash-out
during portal venous and late phase (6.2%, 2/32). The char-
acteristic imaging features of SHCC is centripetal and pro-
longed enhancement during multiphasic dynamic imaging
[1,2]. In this case, the imaging feature of contrast-enhanced
CT and MRI was very special, characterized by light hetero-
geneous enhancement in the arterial phase, ring and prolongeds at the margin, cords of tumor cells of SHCC embedded in an abundant fibrous
eosin,  200).
140 F. Chen et al. / Radiology of Infectious Diseases 2 (2015) 137e140enhancement in the interior of the tumor during portal venous
and equilibrium phases, which did not conform to the imaging
characteristics of SHCC or intrahepatic cholangiocarcinoma
(ICC). Based on these imaging findings, the tumor was diag-
nosed as a hepatic neoplasm only before operation.
SHCC is frequently misdiagnosed as intrahepatic mass-
forming ICC, and combined HCC-CCC or metastatic carci-
noma is characterized by abundant fibrous stroma. The misdi-
agnosis can be attributed to the prolonged enhancement of the
tumor in the equilibrium phase and heterogeneous enhancement
in the arterial phase on contrast-enhanced CT and MRI [9e12].
In summary, radiologists and clinicians engaged in hep-
atology should exercise caution with suspected SHCC when
imaging studies reveal atypical findings, especially as shown
in our case without any liver disease.Author contributionsFeng Chen, Da-Wei Zhao, Hong-Jun Li, Jin-Li Ding
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